CLINICAL EFFECTIVENESS OF DAPAGLIFLOZIN WHEN INCLUDED INTO STANDARD THERAPY FOR CHRONIC HEART FAILURE
Abstract
Chronic heart failure (CHF) is an important problem in cardiology. Timely and competent therapy can not only restore the left ventricular ejection fraction, but also improve the prognosis of patients. The class of sodium-glucose co-transporter type 2 inhibitors (SGLT-2) is recommended as first-line therapy for patients with CHF along with ACEIs/ARNIs, beta blockers and MACRs (evidence class 1A). Dapagliflozin and empagliflozin have been shown to be effective in reducing the risk of adverse outcomes in patients with CHF and have been included in a new quadruple therapy for the treatment of CHF. This article reviews the clinical efficacy of dapagliflozin in patients with heart failure with preserved ejection fraction.
References
1. Ларина В. Н., Замятин К. А., Шерегова Е. Н., Кудинова М. А. Приверженность лечению как неотъемлемый компонент тактики ведения пациентов с хронической сердечной недостаточностью. Российский кардиологический журнал. 2024;29(1):5690.
2. Jingjin Hou, Li Ren, Qingbin Hou, Xiaodong Jia, Zhu Mei et al. Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis Front. Cardiovasc. Med., 11 September 2024Sec. Heart Failure and Transplantation.Volume 11 – 2024.
3. Pabel S., Hamdani N., Luedde M., Sossalla S. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled? Curr Heart FailRep. 2021;18(5):315–328. https://doi.org/10.1007/s11897-021-00529-8.
4. Канорский С.Г. Новые принципы лечения хронической сердечной недостаточности: феномен ингибиторов натрий-глюкозного котранспортера 2-го типа. Медицинский совет. 2022;16(17):44–51. https://doi.org/10.21518/2079-701X-2022-16-17-44-51.
5. Thiele K., Rau M., Hartmann N.K., Möllmann J., Jankowski J., Böhm M. et al. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes Obes Metab. 2021;23(12):2814–2818. https://doi.org/10.1111/dom.14517.
Abdurahimovna, E. I. (2023). BENEFITS OF ENGAGING IN DEBATES FOR ENGLISH AS A SECOND LANGUAGE LEARNERS. Ta'lim innovatsiyasi va integratsiyasi, 11(3), 37-39.
Abdurahimovna, E. I. (2023). USE OF MASS MEDIA CAMPAIGNS TO CHANGE HEALTH BEHAVIOUR. Ta'lim innovatsiyasi va integratsiyasi, 11(3), 43-45.
Abdurahimovna, E. I. (2023). THE ROLE OF COMMUNICATIONAL DEVICES IN CLASSROOM. Ta'lim innovatsiyasi va integratsiyasi, 11(3), 46-49.
Abdurahimovna, E. I. (2023). THE INTERNET IS SOME NEGATIVE FOR LANGUAGES EFFECTS. Ta'lim innovatsiyasi va integratsiyasi, 11(3), 40-42.
Abdurahimovna, E. I. (2023). THE IMPACT OF MASS MEDIA ON LANGUAGE LEARNING: EXPANDING HORIZONS THROUGH MULTIFACETED ENGAGEMENT. O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIY TADQIQOTLAR JURNALI, 2(25), 200-203.
Abdurahimovna, E. I. (2023). LEVERAGING BODY LANGUAGE: ENHANCING FOREIGN LANGUAGE INSTRUCTION IN THE CLASSROOM. O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIY TADQIQOTLAR JURNALI, 2(25), 188-191.
